Medicare weighs cost, benefit of covering Dendreon’s Provenge for prostate cancer
July 2nd, 2010 admin
Topics:
The announcement that the Centers for Medicare and medicaid services would do this analysis “was the latest hurdle in Dendreon’s push to get its Provenge treatment used. If the Centers for Medicare and medicaid services covers Provenge, that would increase the number of patients eligible and likely force private insurers to do the same. [Original News
Related Posts
WHAT’S HAPPENING: Medicare will spend a year deciding whether to cover Dendreon Corp.’s prostate cancer therapy Provenge, which costs $93,000 for a course of treatment. [Original News Article] Related NewsDendreon: Medicare reviews Provenge costsDendreon: Medicare reviewing Provenge coverageMedicare weighs cost, benefit of covering Dendreon’s...
New York _ Medicare administrators say they will take a full year to review Dendreon Corp.’s prostate cancer therapy Provenge and decide whether to cover the costly treatment. Provenge, which costs $93,000 for a course of treatment, has been widely expected… Dendreon – Prostate cancer – Sipuleucel-T – Cancer – Medicare...
Medicare says it initiated a rare coverage analysis for the prostate cancer treatment because of the [Original News Article] Related NewsDendreon: Medicare reviewing Provenge coverageDendreon: Medicare reviews Provenge costsMedicare to Take a Year For Provenge Coverage Decision
Read More →
Medicare Considers Dendreon Cancer Treatment [Original News Article] Related NewsDendreon: Medicare reviewing Provenge coverageMedicare looking at Dendreon cancer vaccineDendreon: Medicare reviews Provenge costs
Read More →
Summary : I’m crossing posting this piece from Dr. Len’s Cancer Blog http://www.cancer.org/aspx/blog/Comments.aspx?id=353 because it seems to me a very wise and balanced assessment of what Provenge means—and doesn’t mean—for patients, for Medicare and for society as a whole. I’ve highlighted some sentences, and inserted a few comments...
Dendreon Corp. said Medicare administrators are conducting a review to determine whether the health agency will cover the costs of its prostate cancer therapy Provenge. [Original News Article] Related NewsSummary Box: Medicare reviews Dendreon’s ProvengeDendreon: Medicare reviewing Provenge coverageMedicare weighs cost, benefit of covering Dendreon’s...
A Medicare panel will weigh the pros and cons of radiation therapy, including some types of treatment available in Southwest Florida, against monitoring patients [Original News Article] Related NewsMedicare may stop covering device used in prostate, ovarian cancer treatmentFlorida Medicare provider won’t cut cancer treatmentChanges In Medicare...
Medicare sets a Nov. 17 meeting to discuss Dendreon’s Provenge, but the focus will be on which patients should get the prostate cancer vaccine, not whether to cover it at all. [Original News Article] Related NewsDendreon: Medicare reviewing Provenge coverageDendreon Gets Date for Medicare MeetingMedicare Considers Dendreon Cancer Treatment
Read More →
Cancer centers are using waiting lists and techniques borrowed from the organ-transplant world to distribute Provenge as equitably as is possible.
Read More →
Here’s what you need to know about Medicare’s decision to weigh national coverage for Dendreon’s prostate cancer therapy Provenge. [Original News Article] Related NewsDendreon: Medicare reviewing Provenge coverageMedicare Considers Dendreon Cancer TreatmentDendreon: Medicare reviews Provenge costs
Read More →
Related Tweets from Twitter
Related News from Digg
Leave a comment
| Trackback
